232 related articles for article (PubMed ID: 24804929)
21. Effect of different doses and durations of teriparatide therapy on resolution of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats.
Zandi M; Dehghan A; Zandipoor N; Amini P; Doulati S
J Craniomaxillofac Surg; 2018 Mar; 46(3):466-472. PubMed ID: 29395991
[TBL] [Abstract][Full Text] [Related]
22. Osteonecrosis after administration of intravitreous bevacizumab.
Hopp RN; Pucci J; Santos-Silva AR; Jorge J
J Oral Maxillofac Surg; 2012 Mar; 70(3):632-5. PubMed ID: 21757280
[No Abstract] [Full Text] [Related]
23. The relationship of denosumab pharmacology and osteonecrosis of the jaws.
Malan J; Ettinger K; Naumann E; Beirne OR
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Dec; 114(6):671-6. PubMed ID: 23159111
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy.
Lee JJ; Cheng SJ; Jeng JH; Chiang CP; Lau HP; Kok SH
Head Neck; 2011 Sep; 33(9):1366-71. PubMed ID: 20310042
[TBL] [Abstract][Full Text] [Related]
25. A new class of drugs to prevent osteoporosis may be associated with osteonecrosis of the jaw.
Wynn RL
Gen Dent; 2011; 59(1):10-2. PubMed ID: 21613033
[No Abstract] [Full Text] [Related]
26. Bisphosphonate treatment as a cause of jaw osteonecrosis.
Kanat O; Ozet A; Ataergin S; Kuzhan O; Arpaci F; Ozturk B; Komurcu S; Ozturk M
Oral Dis; 2007 May; 13(3):346-7. PubMed ID: 17448221
[No Abstract] [Full Text] [Related]
27. Treating osteoporosis.
Smith G; Stassen L; Flint S
Ir Med J; 2009 Mar; 102(3):88; author reply 89. PubMed ID: 19489199
[No Abstract] [Full Text] [Related]
28. Denosumab-related osteonecrosis of the jaws.
Kyrgidis A; Toulis KA
Osteoporos Int; 2011 Jan; 22(1):369-70. PubMed ID: 20306021
[No Abstract] [Full Text] [Related]
29. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
30. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
O'Halloran M; Boyd NM; Smith A
Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
[TBL] [Abstract][Full Text] [Related]
31. Denosumab-Related Osteonecrosis of the Jaw May Not Be a Subject of Teriparatide Treatment.
Park KS; Jung SM; Park YJ; Kim KJ
J Bone Miner Res; 2022 Oct; 37(10):2044-2045. PubMed ID: 35751544
[No Abstract] [Full Text] [Related]
32. Osteonecrosis of the jaw related to the use of bisphosphonates.
Van den Wyngaert T; Huizing MT; Vermorken JB
Curr Opin Oncol; 2007 Jul; 19(4):315-22. PubMed ID: 17545793
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonate-induced osteonecrosis of the jaw.
Sharma V; Nagaraj S; Choksey U; Hegde A; Samant R; Balakrishnan C
J Assoc Physicians India; 2011 Aug; 59():516-7. PubMed ID: 21887911
[TBL] [Abstract][Full Text] [Related]
34. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw.
Cicciù M; Herford AS; Juodžbalys G; Stoffella E
J Craniofac Surg; 2012 May; 23(3):784-8. PubMed ID: 22565901
[TBL] [Abstract][Full Text] [Related]
36. Management of bisphosphonate-related osteonecrosis of the jaw: a literature review.
Spanou A; Lyritis GP; Chronopoulos E; Tournis S
Oral Dis; 2015 Nov; 21(8):927-36. PubMed ID: 25732104
[TBL] [Abstract][Full Text] [Related]
37. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
Fedele S; Porter SR; D'Aiuto F; Aljohani S; Vescovi P; Manfredi M; Arduino PG; Broccoletti R; Musciotto A; Di Fede O; Lazarovici TS; Campisi G; Yarom N
Am J Med; 2010 Nov; 123(11):1060-4. PubMed ID: 20851366
[TBL] [Abstract][Full Text] [Related]
38. Comments on ''Geranylgeraniol--a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw" by Ziebart T et al. (2011).
Marcuzzi A; Zanin V; Crovella S; Pontillo A
Oral Oncol; 2011 May; 47(5):436-7; author reply 438. PubMed ID: 21411362
[No Abstract] [Full Text] [Related]
39. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate-related osteonecrosis of the jaw.
Feller L; Wood NH; Khammissa RA; Chikte UM; Bouckaert M; Lemmer J
SADJ; 2011 Feb; 66(1):30-2. PubMed ID: 21510174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
